Loading organizations...
Crescendo Biologics is a technology company.
Crescendo Biologics develops novel T-cell enhancing therapeutics for immuno-oncology. Its proprietary platform creates fully human VH domains, known as Humabodies. These single-domain antibodies are engineered for precise targeting and potent biological activity, enabling the development of multi-specific agents that activate the immune system against cancer.
Crescendo Biologics was established in 2007 by Mike Romanos, a scientist experienced in antibody drug discovery. Romanos founded the company with the insight that smaller, single-domain antibody fragments offer advantages over conventional antibodies. These benefits include improved tissue penetration and the modularity essential for designing complex multi-specific drug candidates.
The company’s product candidates are ultimately intended for cancer patients, offering new therapeutic options by precisely harnessing the body's immune system. Crescendo Biologics strives to lead the field in developing next-generation precision immunotherapies. Its vision is to transform cancer treatment, providing effective T-cell enhancing therapies.
Crescendo Biologics has raised $140.9M across 5 funding rounds.
Crescendo Biologics has raised $140.9M in total across 5 funding rounds.
Crescendo Biologics has raised $140.9M in total across 5 funding rounds.
Crescendo Biologics's investors include Andera Partners, Sonia Benhamida, Quan Capital, Sofinnova Partners, Takeda, Gilles Nobécourt, Soffinova Partners, Biodiscovery V, EMBL Ventures, Marietta Wu, Takeda Ventures, Imperial Innovations.
Crescendo Biologics is a privately-held, clinical-stage biotechnology company developing novel, targeted T cell enhancing therapeutics for immuno-oncology.[1][3][4] It leverages a rapid discovery process and fully human VH domain-based Humabodies to create immune cell enhancing drugs, addressing unmet needs in cancer treatment by boosting T cell activity.[3][5] The company serves patients with solid tumors and other cancers, solving the problem of insufficient immune response through precise, differentiated biologics; it remains active with recent accounts to December 2024, indicating ongoing operations and growth momentum in biotech R&D.[2]
Crescendo Biologics was incorporated on 13 November 2007 as Translocus Limited, a UK private limited company focused on biotechnology research (SIC 72110).[2] It rebranded to Crescendo Biologics on 16 March 2009, shifting emphasis to immuno-oncology therapeutics based on antibody fragment technology.[2][5] Headquartered in Cambridge, England, the company emerged from early innovation in Humabody VH domains, achieving clinical-stage status through pivotal advancements in T cell enhancement, with steady filing history reflecting sustained development.[1][2][3]
Crescendo Biologics rides the immuno-oncology wave, capitalizing on surging demand for T cell therapies amid advances in precision medicine and biologics.[1][3][4] Timing aligns with post-2020 clinical successes in checkpoint inhibitors and CAR-T, where antibody fragments like Humabodies offer advantages in tumor penetration and modularity.[5] Favorable market forces include biotech funding resurgence and regulatory nods for novel modalities, positioning Cambridge's biotech cluster as a hub; the company influences the ecosystem by advancing VH domain tech, potentially enabling partnerships and licensing in the $100B+ oncology market.[1][2]
Next steps likely involve advancing clinical trials for lead T cell enhancers, with accounts due in 2026 signaling pipeline maturation.[2] Trends like bispecific antibodies and AI-driven discovery will shape progress, amplifying Humabody scalability. Influence may evolve through acquisitions or alliances, solidifying its role in next-gen immuno-oncology—echoing its origins as a targeted innovator tackling cancer's immune evasion.[3][4]
Crescendo Biologics has raised $140.9M across 5 funding rounds. Most recently, it raised $32.0M Other Equity in July 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 24, 2023 | $32.0M Other Equity | Andera Partners, Sonia Benhamida, Quan Capital, Sofinnova Partners, Takeda | |
| Apr 1, 2018 | $70.0M Series B | Gilles Nobécourt | Soffinova Partners, Biodiscovery V, EMBL Ventures, Marietta Wu, Takeda Ventures |
| Apr 3, 2014 | $3.3M Series A Extension | Imperial Innovations | Astellas Venture Management, EMBL Ventures, Sofinnova Partners |
| Dec 17, 2013 | $28.4M Series A | Rob Woodman | Astellas Venture Management, Sofinnova Partners |
| Oct 12, 2009 | $7.2M Seed | Sofinnova Partners | Aitua, Avlar BioVentures, Rainbow Seed Fund |